Ftse Mib
34.556,03
0,28%
DAX
18.730,65
0,26%
S&P 500
5.307,01
-0,27%
NASDAQ
0,00
0,00%
Bitcoin
69.905,03
1,16%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ C4 Therapeutics Inc (CCCC) C4 Therapeutics Inc (CCCC) Notizie

CCCC

C4 Therapeutics (CCCC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CCCC
DataOraFonteTitoloSimboloCompagnia
08/05/202413:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CCCCC4 Therapeutics Inc
08/05/202413:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
08/05/202413:00GlobeNewswire Inc.C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
29/04/202422:01GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
09/04/202413:00GlobeNewswire Inc.C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumNASDAQ:CCCCC4 Therapeutics Inc
08/04/202414:00GlobeNewswire Inc.C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
09/03/202401:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
05/03/202422:30GlobeNewswire Inc.C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
04/03/202413:00GlobeNewswire Inc.C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsNASDAQ:CCCCC4 Therapeutics Inc
22/02/202415:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CCCCC4 Therapeutics Inc
22/02/202413:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CCCCC4 Therapeutics Inc
22/02/202413:00GlobeNewswire Inc.C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
14/02/202415:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CCCCC4 Therapeutics Inc
05/02/202416:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CCCCC4 Therapeutics Inc
09/01/202422:01GlobeNewswire Inc.C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation MedicinesNASDAQ:CCCCC4 Therapeutics Inc
04/01/202422:01GlobeNewswire Inc.C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta PharmaceuticalsNASDAQ:CCCCC4 Therapeutics Inc
04/01/202413:00GlobeNewswire Inc.C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CCCCC4 Therapeutics Inc
12/12/202322:01GlobeNewswire Inc.C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple MyelomaNASDAQ:CCCCC4 Therapeutics Inc
12/12/202315:15AllPennyStocks.comBiotech Catches Major Premarket BidNASDAQ:CCCCC4 Therapeutics Inc
12/12/202313:00GlobeNewswire Inc.C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)NASDAQ:CCCCC4 Therapeutics Inc
28/11/202313:00GlobeNewswire Inc.C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple MyelomaNASDAQ:CCCCC4 Therapeutics Inc
20/11/202313:00GlobeNewswire Inc.C4 Therapeutics Strengthens Board of Directors with Owen Hughes AppointmentNASDAQ:CCCCC4 Therapeutics Inc
01/11/202312:00GlobeNewswire Inc.C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
11/10/202313:00GlobeNewswire Inc.C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple MyeNASDAQ:CCCCC4 Therapeutics Inc
20/09/202301:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
05/09/202322:01GlobeNewswire Inc.C4 Therapeutics Announces Chief Financial Officer SuccessionNASDAQ:CCCCC4 Therapeutics Inc
08/08/202313:00GlobeNewswire Inc.C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
17/07/202313:00GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
05/07/202316:30Dow Jones NewsC4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA ClearanceNASDAQ:CCCCC4 Therapeutics Inc
05/07/202313:00GlobeNewswire Inc.C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung CancerNASDAQ:CCCCC4 Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CCCC

La tua Cronologia

LSE
FIT
Framlington
LSE
48DW
Rmpa 5.337%
USOTC
FQVTF
FeverTree Drinks (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network